Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (81-90 of 361) with videos related to

Pageof 37
Sort By:
BJU International|October 10, 2007
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102George K Philips, Susan Halabi, Ben L Sanford, et al.
The Journal of Urology|July 20, 2002
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancerKatherine A Harris, Vivian Weinberg, Robert A Bok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinomaBrian I Rini, Susan Halabi, John Taylor, et al.
Urologic Oncology|September 12, 2006
Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURECharles J Ryan, Eric P Elkin, Eric J Small, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancerEric J Small, Matthew R Smith, John J Seaman, et al.
The Journal of Urology|June 7, 2006
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studiesSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583Susan Halabi, Eric J Small, Daniel F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2013
Reply to C.M. Booth et alPamela J Goodwin, Karla V Ballman, Eric J Small, et al.
Clinical Genitourinary Cancer|October 10, 2009
The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levelsRahul Aggarwal, Vivian Weinberg, Eric J Small, et al.
Cancer|April 4, 2003
Overview of bladder cancer trials in the Cancer and Leukemia Group BEric J Small, Susan Halabi, Guido Dalbagni, et al.
Pageof 37

Showing results (81-90 of 361) with videos related to

Sort By:
Pageof 37
BJU International|October 10, 2007
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102George K Philips, Susan Halabi, Ben L Sanford, et al.
The Journal of Urology|July 20, 2002
Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancerKatherine A Harris, Vivian Weinberg, Robert A Bok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinomaBrian I Rini, Susan Halabi, John Taylor, et al.
Urologic Oncology|September 12, 2006
Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURECharles J Ryan, Eric P Elkin, Eric J Small, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2003
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancerEric J Small, Matthew R Smith, John J Seaman, et al.
The Journal of Urology|June 7, 2006
Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studiesSusan Halabi, Nicholas J Vogelzang, San-San Ou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583Susan Halabi, Eric J Small, Daniel F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2013
Reply to C.M. Booth et alPamela J Goodwin, Karla V Ballman, Eric J Small, et al.
Clinical Genitourinary Cancer|October 10, 2009
The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levelsRahul Aggarwal, Vivian Weinberg, Eric J Small, et al.
Cancer|April 4, 2003
Overview of bladder cancer trials in the Cancer and Leukemia Group BEric J Small, Susan Halabi, Guido Dalbagni, et al.
Pageof 37